טקרוסל 0.5 מג
padagis israel agencies ltd, israel - tacrolimus as monohydrate - קפסולות - tacrolimus as monohydrate 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.
טקרוסל 1 מג
padagis israel agencies ltd, israel - tacrolimus as monohydrate - קפסולות - tacrolimus as monohydrate 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.
טקרוסל 5 מג
padagis israel agencies ltd, israel - tacrolimus as monohydrate - קפסולות - tacrolimus as monohydrate 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.
טיגציל
pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu
טיגציל
pfizer pfe pharmaceuticals israel ltd - tigecycline - אבקה להכנת תמיסה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu
צפזולין סנדוז 0.5 גרם
masrouji company ltd - cefazolin as sodium 500 mg/vial - powder for solution for injection - cefazolin - treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. treatment respiratory tract: respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group a b - hemolytic streptococci. cefazolin is effective in the eradication of streptococci from the nasopharynx. however data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. urinary tract: infections due to escherichia coli klebsiella species proteus mirabilis and some strains of enterobacter and enterococci. skin and skin structure: -hemolytic beta infections due to staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group a streptococci and other strains of streptococci. biliary tract: infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella
צפאזול 1 גרם
novartis israel ltd - cefazolin as sodium - אבקה להכנת תמיסה לזריקה - cefazolin as sodium 1 g/vial - cefazolin - cefazolin - treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. treatment respiratory tract: respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group a b - hemolytic streptococci. cefazolin is effective in the eradication of streptococci from the nasopharynx. however data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. urinary tract: infections due to escherichia coli klebsiella species proteus mirabilis and some strains of enterobacter and enterococci. skin and skin structure: -hemolytic beta infections due to staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group a streptococci and other strains of streptococci. biliary tract: infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella
מגאקסין iv
bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.
מגאקסין iv
bayer israel ltd - moxifloxacin - תמיסה לאינפוזיה - moxifloxacin 400 mg / 250 ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.
קלטרה תמיסה
abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir